EDIT
Editas Medicine, Inc. · Healthcare · Market cap $385.5M
Insiders sold $34K net in the last 90 days ·3 sellers, 0 buyers· latest Form 4 filed Sep 4, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$107K
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Sep 4, 2026
Parison Amy
Editas Medicine, Inc. (EDIT) has 14 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Sep 4, 2026.
Inside the rolling window, 3 insiders at Editas Medicine, Inc. reported no open-market purchases and 14 open-market sales totaling $107K. The most active filer is SVP, Chief Financial Officer Parison Amy with 5 filings. The most recent open-market filing is a sale of 453 shares by SVP, Chief Financial Officer Parison Amy, dated Sep 3, 2026, worth $1K.
- Industry:Biotechnology
- CEO:Gilmore O'Neill
- Employees:87
- HQ:Cambridge, MA, US
- IPO:2016-02-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
| SVP, Chief Financial Officer | Sale | 453 | $1K | Sep 4 | -22.3% | SEC ↗ | |
O'Neill Gilmore NeilFirst in 3 months | CEO | Sale | 5,124 | $16K | Sep 4 | -22.3% | SEC ↗ |
| EVP, CHIEF SCIENTIFIC OFFICER | Sale | 709 | $2K | Sep 4 | -22.3% | SEC ↗ | |
| SVP, Chief Financial Officer | Sale | 678 | $2K | Aug 5 | -8.7% | SEC ↗ | |
| EVP, CHIEF SCIENTIFIC OFFICER | Sale | 4,928 | $13K | Jul 29 | -3.5% | SEC ↗ | |
Burkly LindaFirst in 3 months | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2K | Jun 5 | -7.4% | SEC ↗ |
Parison AmyFirst in 3 months | SVP, Chief Financial Officer | Sale | 464 | $1K | Jun 5 | -7.4% | SEC ↗ |
O'Neill Gilmore NeilFirst in 3 months | CEO | Sale | 15,380 | $42K | Jun 5 | -7.4% | SEC ↗ |
O'Neill Gilmore NeilFirst in 3 months | CEO | Sale | 5,394 | $11K | Mar 4 | +14.6% | SEC ↗ |
Burkly LindaFirst in 3 months | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2K | Mar 4 | +14.6% | SEC ↗ |
Parison AmyFirst in 3 months | SVP, Chief Financial Officer | Sale | 474 | $957 | Mar 4 | — | SEC ↗ |
Burkly LindaFirst filing | EVP, CHIEF SCIENTIFIC OFFICER | Sale | 713 | $2K | Dec 4 | — | SEC ↗ |
Parison AmyFirst filing | SVP, Chief Financial Officer | Sale | 461 | $993 | Dec 4 | — | SEC ↗ |
O'Neill Gilmore NeilFirst filing | CEO | Sale | 5,603 | $12K | Dec 4 | — | SEC ↗ |
Congress trading EDIT 14 all-time
- DRep. Daniel GoldmanSale$1,001 - $15,0002023-04-10
- DRep. Donald Sternoff BeyerOther$1,001 - $15,0002021-04-14
- DRep. Donald Sternoff BeyerOther$1,001 - $15,0002021-03-02
- DRep. Donald Sternoff BeyerPurchase$1,001 - $15,0002020-11-17
- DRep. Donald Sternoff BeyerOther$1,001 - $15,0002020-05-01
- DRep. Donald Sternoff BeyerOther$1,001 - $15,0002020-04-27
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does EDIT have?
Editas Medicine, Inc. (EDIT) has 14 SEC Form 4 filings (14 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Sep 4, 2026.
When was the most recent SEC Form 4 filing for EDIT?
The most recent Form 4 filing for EDIT on Tracefour is dated Sep 4, 2026.
Who is the most active insider at EDIT?
The most active SEC Form 4 filer at EDIT in the rolling window is SVP, Chief Financial Officer Parison Amy, with 5 filings.
What is the net insider flow at EDIT over the last 6 months?
Over the trailing 180 days, insiders at EDIT have net sold $79K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at EDIT in the current window?
Inside the rolling window, insiders at EDIT bought $0 and sold $107K based on SEC Form 4 filings.
Can I get alerts for EDIT insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Editas Medicine, Inc. (EDIT). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Editas Medicine, Inc. is in the Healthcare sector.